Communiqués NewAmsterdam Pharma Company N.V. Börse Stuttgart

Actions

KH6

NL00150012L7

Recherche biotechnologique et médicale

Temps réel estimé Tradegate Autres places de cotation 12:56:48 31/07/2026			Varia. 5j.	Varia. 1 janv.
24,90 ^EUR	+0,77%		-12,60%	-17,42%

24/07	NewAmsterdam Pharma : le comité de l'EMA recommande l'approbation de traitements contre le cholestérol	MT
24/07	NewAmsterdam Pharma et le Groupe Menarini reçoivent un avis positif du CHMP recommandant l'autorisation de mise sur le marché d'Ubeslo (obicetrapib en monothérapie) et d'Evlarco (combinaison à dose fixe obicetrapib et ézétimibe)	CI

Communiqués

29/07	NewAmsterdam Pharma to Host Investor Day on August 5, 2026	GL
27/07	NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo and Evlarco	AQ
24/07	NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)	GL
08/07	Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma	AQ
02/07	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
01/07	NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026	GL
03/06	NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions	GL
03/06	NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions	AQ
28/05	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June	GL
11/05	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May	GL
07/05	Frazier Lifesciences Acquisition : NewAmsterdam Pharma PREVAIL Update May 2026	PU
07/05	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	GL
07/05	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	AQ
01/05	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
08/04	NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference	GL
08/04	NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference	AQ
02/04	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
26/03	Safety of Obicetrapib: An Integrated Pooled Phase III Safety Analysis	PU
26/03	Frazier Lifesciences Acquisition : Cardiovascular Events in People with Discordantly High Levels of Small Medium LDL Particles	PU
26/03	CETP Inhibition With Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results From the BROADWAY Trial	PU
24/03	CETP Inhibition With Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results From the BROADWAY Trial	PU
23/03	NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session	GL
09/03	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
06/03	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
27/02	Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia: The BROOKLYN Randomized Clinical Trial	PU